ESTRO 2025 - Abstract Book

S3901

Radiobiology - Microenvironment

ESTRO 2025

Conclusion: We presented a PDAC on a chip preclinical model. This model joins key structural and biochemical factors associated with chemo- and radioresistance (i.e., PSCs, cell spatial organization, TGF-β, stroma mechanical properties, tissue-specific microvasculature), offering the opportunity to assess their role in PDAC therapy response. Given the earlier evidence on chip compatibility with radiation therapy [5,6], this device enables preclinical testing of tumor radiobiology on-chip.

Keywords: Tumor-on-chip, PDAC, Tumor Spheroids

References: 1. M. N. C. Institute, PDQ® Adult Treatment Editorial Board (2024) 2. Pandol, S. et al. doi: 10.1016/j.cgh.2009.07.039. Clinical Gastroenterology and Hepatology , 7 (11S 3. Chen, M. B. et al. doi: 10.1038/nprot.2017.018. Nat Protoc 12, 865–880 (2017) 4. Possenti, L. et al. doi: 10.3390/cancers13051182. Radiotherapy and Oncology 182, S57–S58 (2023) 5. Guo, Z. et al. doi: 10.1002/admt.201800726. Adv Mater Technol 4, 1–12 (2019) Acknowledgments: this work was funded by 5xmille funds for healthcare research (Ministry of Health).

UPPL) (2009) .